Dydrogesterone
Trials 51 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06546397 | May 2024 → Sep 2025 overdue | pregnancy disorder | Women's Hospital School Of Medicine Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT05678192 | Dec 2021 → Mar 2023 | — | Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04175990 | May 2018 → Mar 2019 | ovarian hyperstimulation syndrome | National University of Malaysia | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02726971 | Apr → Aug 2016 | Asherman syndrome | Fu Xing Hospital, Capital Medical University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06212102 | May 2024 → Mar 2027 expected | infertility disorder | Bedaya Hospital | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05951400 | Jan 2024 → Mar 2026 | — | Beni-Suef University | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT05972902 | Jul → Dec 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT06868576 | Jan 2023 → Oct 2024 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03859921 | Jul 2021 → Dec 2025 overdue | infertility disorder | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT04414748 | Jun 2020 → Dec 2024 | — | ShangHai Ji Ai Genetics & IVF Institute | Completed | No outcome recorded |
| Phase 3 | NCT04414761 | Jun 2020 → Oct 2022 | — | ShangHai Ji Ai Genetics & IVF Institute | Completed | No outcome recorded |
| Phase 3 | NCT03675139 | Feb 2019 → May 2022 | endometrial hyperplasia without atypia | Xiaojun Chen | Completed | No outcome recorded |
| Phase 3 | NCT02989519 | Aug 2015 → Jan 2017 | — | Sanpasitthiprasong Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02491437 | Jul 2015 → May 2017 | female infertility | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01850030 | Aug 2013 → Mar 2016 | female infertility | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00160316 | Apr 2005 → Dec 2007 | — | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00193674 | Sep 2003 → Jul 2009 | pregnancy loss, recurrent, 4 | Abbott Products | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07580950 | Oct 2025 → Jun 2028 expected | functional hypothalamic amenorrhea | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06396390 | Aug 2024 → Jun 2026 overdue | infertility disorder | Nesta Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05156814 | Nov 2021 → Sep 2022 | — | Scientific Research Institute of Public Health, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT05021094 | Oct 2021 → Dec 2023 | primary ovarian failure | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 4 | NCT04758871 | Oct 2021 → Sep 2023 | female infertility | CRG UZ Brussel | Completed | No outcome recorded |
| Phase 4 | NCT03948022 | Jun → Dec 2021 | low implantation of placenta, pregnancy disorder with abortive outcome | Centrum Clinic IVF Center | Completed | No outcome recorded |
| Phase 4 | NCT03858049 | May 2019 → Oct 2021 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 4 | NCT03677336 | May 2019 → Aug 2020 | female infertility, male reproductive system disorder | CRG UZ Brussel | Completed | No outcome recorded |
| Phase 4 | NCT03790215 | Feb → Sep 2019 | endometrial polyp | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04124913 | Jan → Oct 2019 | female infertility, male infertility | Memorial Sisli Hospital, Istanbul | Unknown | No outcome recorded |
| Phase 4 | NCT04762316 | Jan 2019 → Dec 2025 | uterine corpus leiomyoma | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT03619707 | Aug 2018 → Aug 2021 | infertility disorder | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03267771 | Oct 2017 → Aug 2019 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02990403 | Oct 2014 → Jun 2017 | pregnancy loss, recurrent, 4 | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03436303 | Feb 2014 → Jun 2018 | — | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02264743 | Nov 2013 → Nov 2014 | venous thromboembolism | Royal Brompton & Harefield NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 4 | NCT02620345 | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00145522 | Nov 2005 → Mar 2009 | — | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07496294 | Apr 2026 → Oct 2027 expected | — | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07409493 | Jan 2026 → Jun 2028 expected | infertility disorder | Hanoi Medical University | Recruiting | No outcome recorded |
| — | NCT07608133 | Dec 2025 → Apr 2026 | — | Pakistan Air Force (PAF) Hospital Islamabad | Completed | No outcome recorded |
| — | NCT07242131 | Dec 2025 → Jun 2026 overdue | polycystic ovary syndrome | Ege University | Recruiting | No outcome recorded |
| — | NCT05767086 | Mar 2023 → Sep 2024 | infertility disorder | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT05751681 | Feb 2023 → Apr 2024 | infertility disorder, ovarian cyst | Zagazig University | Unknown | No outcome recorded |
| — | NCT04408144 | Apr → May 2022 | infertility disorder | Laniado Hospital | Unknown | No outcome recorded |
| — | NCT03680053 | Apr 2020 → May 2025 | infertility disorder | ShangHai Ji Ai Genetics & IVF Institute | Terminated | No outcome recorded |
| — | NCT05189145 | Oct 2019 → Mar 2021 | female infertility | Alexandria University | Completed | No outcome recorded |
| — | NCT04052607 | Sep 2019 → Apr 2020 | infertility disorder | Ibn Sina Hospital | Terminated | No outcome recorded |
| — | NCT04287205 | Apr 2019 → Feb 2020 | endometriosis, sexual disorder | Kanuni Sultan Suleyman Training and Research Hospital | Completed | No outcome recorded |
| — | NCT03832699 | Mar 2019 → Oct 2021 | — | Wolfson Medical Center | Unknown | No outcome recorded |
| — | NCT03351205 | Nov 2017 → Nov 2018 | adhesions of uterus | Beijing Obstetrics and Gynecology Hospital | Unknown | No outcome recorded |
| — | NCT03346317 | Nov 2017 → May 2018 | adhesions of uterus | Beijing Obstetrics and Gynecology Hospital | Unknown | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02086032 | Jan 2014 → Jun 2015 | — | Chiang Mai University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 33 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05300841 Comparator | May 2022 → Apr 2023 | polycystic ovary syndrome | Sohag University | Unknown | No outcome recorded |
| Phase 0 | NCT03456570 Comparator | May 2018 → May 2020 | ovarian cyst | Assiut University | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06560814 Comparator | Jul 2020 → Jun 2021 | endometriosis, female infertility | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT03794037 Comparator | Dec 2018 → Dec 2023 | ovarian hyperstimulation syndrome | Benha University | Suspended | No outcome recorded |
| Phase 2 | NCT03166189 Background | Dec 2017 → Mar 2019 | Asherman syndrome, female infertility of uterine origin | D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology | Completed | No outcome recorded |
| Phase 2 | NCT03537287 Comparator | Jul 2016 → Jul 2018 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05758064 Comparator | Jan → Dec 2023 | — | El Shatby University Hospital for Obstetrics and Gynecology | Unknown | No outcome recorded |
| Phase 2/3 | NCT03428685 Comparator | Jan 2019 → Jan 2021 | — | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2/3 | NCT02706470 Comparator | May 2016 → Feb 2018 | pregnancy loss, recurrent, 4 | Fudan University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01300676 Comparator | Mar 2009 → Jan 2010 | — | Universiti Sains Malaysia | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05467852 Comparator | Dec 2022 → Jan 2025 | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04537078 Comparator | Sep 2020 → Mar 2021 | female infertility | El Shatby University Hospital for Obstetrics and Gynecology | Completed | No outcome recorded |
| Phase 3 | NCT02128685 Comparator | Mar 2016 → May 2018 | pregnancy disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00251082 Comparator | Dec 2005 → Oct 2007 | — | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04788108 Comparator | Aug 2021 → Aug 2022 | pregnancy disorder | Chulalongkorn University | Completed | No outcome recorded |
| Phase 4 | NCT03935152 Comparator | May 2019 → May 2020 | — | Chulalongkorn University | Completed | No outcome recorded |
| Phase 4 | NCT03620929 Background | Aug 2018 | Asherman syndrome | Fu Xing Hospital, Capital Medical University | Unknown | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07409792 Background | Feb 2026 → Jan 2027 expected | anxiety, depressive disorder, female infertility, sleep disorder | Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT07416578 Background | Jan → Dec 2026 expected | adhesions of uterus | Sixth Affiliated Hospital, Sun Yat-sen University | Active not recruiting | No outcome recorded |
| — | NCT06378268 Comparator | Apr 2024 → Jun 2026 overdue | — | My Duc Hospital | Active not recruiting | No outcome recorded |
| — | NCT07422506 Background | Jan 2024 → Jan 2030 expected | pregnancy disorder with abortive outcome | The Third Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| — | NCT05847660 Comparator | Jun 2023 → Jun 2024 | infertility disorder, polycystic ovary syndrome | Fayoum University | Unknown | No outcome recorded |
| — | NCT05521828 Background | Apr 2023 → Sep 2024 | — | CRG UZ Brussel | Unknown | No outcome recorded |
| — | NCT05112692 Comparator | Nov 2021 → Nov 2023 | polycystic ovary syndrome | Mansoura University | Unknown | No outcome recorded |
| — | NCT05939284 Comparator | Jun 2021 → Sep 2022 | polycystic ovary syndrome | Zagazig University | Completed | No outcome recorded |
| — | NCT05569577 Background | Jan 2021 → Dec 2025 overdue | rubeosis iridis | Fudan University | Recruiting | No outcome recorded |
| — | NCT05437471 Comparator | Jan 2020 → Dec 2021 | pregnancy loss, recurrent, 4 | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| — | NCT03998761 Comparator | Jun 2019 → Jan 2021 | infertility disorder | My Duc Hospital | Completed | No outcome recorded |
| — | NCT03329898 Background | Oct 2017 → Oct 2018 | adhesions of uterus | Beijing Obstetrics and Gynecology Hospital | Unknown | No outcome recorded |
| — | NCT06132620 Comparator | Apr 2017 → Jun 2018 | — | Yun Chen | Completed | No outcome recorded |
| — | NCT02262481 Comparator | Aug 2014 → Jun 2015 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT02496052 Background | Jan 2013 → Jan 2017 | adhesions of uterus | Beijing Obstetrics and Gynecology Hospital | Unknown | No outcome recorded |
| — | NCT01178931 Comparator | Oct 2010 → Oct 2013 | — | University of Zagreb | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 86 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dydrogesterone | “Patients in the control group will receive artificial cycle therapy post-IVF-ET: progesterone injection 40 mg/day, or oral dydrogesterone tablets (Duphaston) 20 mg/day, or...” NCT07409792 ↗77“The objective of the investigator's study is to demonstrate the superiority of oral dydrogesterone (Duphaston) 10 over MVP (Utrogestan) used for luteal supplementation in...” NCT03619707 ↗ “Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).” NCT06132620 ↗ “Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day.” NCT06396390 ↗ “Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day” NCT05939284 ↗ “Group A administered Femoston Conti - oral oestradiol 17β 0.5 mg/dydrogesterone 2.5 mg daily for the duration of the treatment phase (24 weeks)” NCT02264743 ↗ “1 day after medical abortion, give oral estradiol valerate, 1 mg Bid, for 21 days, and add dydrogesterone 10 mg Bid for the next 7 days.” NCT07422506 ↗ “or (2) the PPOS group: dydrogesterone from the first day of ovarian stimulation till the day of ovulation trigger.” PMID 38521533 ↗ Mar 2024 “Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge.” NCT04052607 ↗ “Pregnenolone 60mg & Pyridoxal Phosphate 20mg & Dydrogesterone 10mg & Impatien balsamina extract 100 mg” NCT04762316 ↗ “Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 6 until the day of trigger.” NCT05521828 ↗ “with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy” NCT03620929 ↗ “Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.” NCT06212102 ↗ “maintenance treatment ("Mirena", "Progesterone", "Dydrogesterone", or combined oral contraceptive)” NCT05945407 ↗ “Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup” NCT03794037 ↗ “gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days.” NCT05021094 ↗ “Dydrogesterone (Duphaston, Abbott company, Illinois, United states) at 20 mg/day” NCT04537078 ↗ “concomitantly with oral Dydrogesterone 20mg daily to prevent premature LH surge” NCT07409493 ↗ “Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added” NCT05189145 ↗ “Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg” NCT05678192 ↗ “Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone)” NCT01300676 ↗ “10 mg of dydrogesterone (Duphaston) was added twice a day for 10 days” NCT07416578 ↗ “Femoston 2/10 (estradiol 2mg / dydrogesterone 10mg), 1 tablet daily.” NCT07580950 ↗ “Group A: oral 10 mg dydrogesterone (Duphaston®, Abbott) twice daily” NCT05758064 ↗ “A yellow tablet contains 2mg estradiol and 10mg dydrogesterone.” NCT02726971 ↗ “30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt)” NCT05847660 ↗ “Dydrogesterone (Duphaston®, Coated Tablets) Plus Estradiol” NCT05156814 ↗ |
| Known as | didroxyprogesterone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05467852 ↗ |
| Known as | Duphaston | “Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott)...” NCT03998761 ↗19“The objective of the investigator's study is to demonstrate the superiority of oral dydrogesterone (Duphaston) 10 over MVP (Utrogestan) used for luteal supplementation in...” NCT03619707 ↗ “The purpose of this clinical study is to demonstrate the shift from inflammatory cytokines to non-inflammatory cytokines in women suffering from habitual abortion treated with...” NCT00193674 ↗ “Luteal support was provided as Crinone 8%(®) vaginal progesterone gel (90mg) administered daily, or oral dydrogesterone Duphaston(®) (2× 10mg) administered two times daily.” PMID 25622239 ↗ Nov 2014 “Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day.” NCT06396390 ↗ “Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle” NCT05300841 ↗ “oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger” NCT04414761 ↗ “Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 6 until the day of trigger.” NCT05521828 ↗ “20 mg Duphaston (Abbott Healthcare Products, B.V., Netherlands) daily from day 15 to day 25” NCT03166189 ↗ “Dydrogesterone (Duphaston, Abbott company, Illinois, United states) at 20 mg/day” NCT04537078 ↗ “10 mg of dydrogesterone (Duphaston) was added twice a day for 10 days” NCT07416578 ↗ “Group A: oral 10 mg dydrogesterone (Duphaston®, Abbott) twice daily” NCT05758064 ↗ “Dydrogesterone (Duphaston®, Coated Tablets) Plus Estradiol” NCT05156814 ↗ “20 mg oral dose of dydrogesterone (Duphaston, Abbott)” NCT05751681 ↗ “oral 10mg dydrogesterone (Duphaston) 2 times daily” NCT04408144 ↗ “oral dydrogesterone tablets (Duphaston) 20 mg/day” NCT07409792 ↗ “Dydrogesterone 10Mg Tablet (duphaston)” NCT03948022 ↗ |
| Known as | DYD | “Dydrogesterone (DYD) is one of the synthetic forms of progesterone” NCT05300841 ↗ |
| Known as | DYG | “Dydrogesterone (DYG), which has a molecular structure similar to that of natural progesterone” NCT05112692 ↗ |
| Action | Inhibit | “to prevent luteinizing hormone (LH) surge” NCT04052607 ↗ |
| Modality | Other / unclassified | “oral progestogen” PMID 33331637 ↗ Feb 2021 |
| Route | Oral | “p.o. daily” NCT00160316 ↗ |